Brief: Fusion Pharmaceuticals Announces Research Collaboration With 48Hour Discovery To Develop Peptide-Based Radiopharmaceuticals
11/01/2022 13:50
Jan 11 (Reuters) - Fusion Pharmaceuticals Inc FUSN.O :
* FUSION PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION
WITH
48HOUR DISCOVERY TO DEVELOP PEPTIDE-BASED RADIOPHARMACEUTICALS
* FUSION PHARMACEUTICALS INC - COLLABORATION TO DISCOVER
NOVEL,
PEPTIDE-BASED RADIOPHARMACEUTICALS FOR TREATMENT OF VARIOUS
SOLID TUMORS.
* FUSION PHARMACEUTICALS INC - FUSION HAS GLOBAL RIGHTS TO
DEVELOP
AND COMMERCIALIZE ANY PEPTIDES DISCOVERED UNDER COLLABORATION.
Source text for Eikon: ID:nPn2tYKPHa
Further company coverage: FUSN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusion Pharmaceuticals
See all newsBrief: Acquisition Of Fusion Pharmaceuticals Completed
Brief: Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Fusion Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary